Research ArticleCancer

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

See allHide authors and affiliations

Science Translational Medicine  11 Apr 2018:
Vol. 10, Issue 436, eaao5931
DOI: 10.1126/scitranslmed.aao5931

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

The personalized touch in cancer vaccination

Transfer of autologous dendritic cells (DCs) has been investigated as a method of boosting T cell responses in therapeutic vaccines for several diseases. Tanyi et al. report the findings of a clinical study involving recurrent ovarian cancer patients. Patient DCs were pulsed with oxidized tumor lysate before transfer and given alone or in combination with immunomodulatory drugs. The DC vaccine was well tolerated and induced potent antitumor T cell responses, including to new epitopes, that correlated with better prognosis. These results suggest further testing of this vaccination regimen for inducing protective T cell immunity in cancer.